Mapping depression rating scale phenotypes onto research domain criteria (RDoC) to inform biological research in mood disorders.

[1]  M. Hamilton.  A RATING SCALE FOR DEPRESSION , 1960, Journal of neurology, neurosurgery, and psychiatry.

[2]  R. R. Parker,et al.  Response to phenelzine and amitriptyline in subtypes of outpatient depression. , 1982, Archives of general psychiatry.

[3]  A. Beck,et al.  Psychometric properties of the Beck Depression Inventory: Twenty-five years of evaluation , 1988 .

[4]  R. Fieve,et al.  Melancholic/endogenous depression and response to somatic treatment and placebo. , 1992, The American journal of psychiatry.

[5]  R. Kessler,et al.  The identification and validation of distinct depressive syndromes in a population-based sample of female twins. , 1996, Archives of general psychiatry.

[6]  M. Fava,et al.  Major depressive subtypes and treatment response , 1997, Biological Psychiatry.

[7]  P. Sullivan,et al.  Latent class analysis of lifetime depressive symptoms in the national comorbidity survey. , 1998, The American journal of psychiatry.

[8]  P. Mitchell,et al.  Subtyping depression: testing algorithms and identification of a tiered model. , 1999, The Journal of nervous and mental disease.

[9]  M. Fava,et al.  Timing of onset of antidepressant response with fluoxetine treatment. , 2000, The American journal of psychiatry.

[10]  P. Sullivan,et al.  The subtypes of major depression in a twin registry. , 2002, Journal of affective disorders.

[11]  F. Quitkin.  Depression With Atypical Features: Diagnostic Validity, Prevalence, and Treatment. , 2002, Primary care companion to the Journal of clinical psychiatry.

[12]  F. Benazzi.  Can only reversed vegetative symptoms define atypical depression? , 2002, European Archives of Psychiatry and Clinical Neuroscience.

[13]  J. Markowitz,et al.  The 16-Item quick inventory of depressive symptomatology (QIDS), clinician rating (QIDS-C), and self-report (QIDS-SR): a psychometric evaluation in patients with chronic major depression , 2003, Biological Psychiatry.

[14]  R. Bagby,et al.  The Hamilton Depression Rating Scale: has the gold standard become a lead weight? , 2004, The American journal of psychiatry.

[15]  A. Gamma,et al.  Atypical depressive syndromes in varying definitions , 2006, European Archives of Psychiatry and Clinical Neuroscience.

[16]  Alan B. Shafer,et al.  Meta-analysis of the factor structures of four depression questionnaires: Beck, CES-D, Hamilton, and Zung. , 2006, Journal of clinical psychology.

[17]  M. Fava,et al.  Response to a selective serotonin reuptake inhibitor (citalopram) in major depressive disorder with melancholic features: a STAR*D report. , 2008, The Journal of clinical psychiatry.

[18]  G. Parker,et al.  Measuring melancholia: the utility of a prototypic symptom approach , 2008, Psychological Medicine.

[19]  A. Beekman,et al.  Identifying depressive subtypes in a large cohort study: results from the Netherlands Study of Depression and Anxiety (NESDA). , 2010, The Journal of clinical psychiatry.

[20]  A. Beekman,et al.  Stability and transitions of depressive subtypes over a 2-year follow-up , 2012, Psychological Medicine.

[21]  Helen S Mayberg,et al.  Predictors of remission in depression to individual and combined treatments (PReDICT): study protocol for a randomized controlled trial , 2012, Trials.

[22]  G. Chrousos,et al.  Melancholic and atypical subtypes of depression represent distinct pathophysiological entities: CRH, neural circuits, and the diathesis for anxiety and depression , 2013, Molecular Psychiatry.

[23]  A. Franco,et al.  Toward a neuroimaging treatment selection biomarker for major depressive disorder. , 2013, JAMA psychiatry.

[24]  D. Schaid,et al.  Treatment Outcomes of Depression: The Pharmacogenomic Research Network Antidepressant Medication Pharmacogenomic Study , 2014, Journal of clinical psychopharmacology.

[25]  Donna M. Palmer,et al.  Depression Subtypes in Predicting Antidepressant Response: A Report From the iSPOT-D Trial. , 2015, The American journal of psychiatry.

[26]  B. Gibb,et al.  Integrating NIMH Research Domain Criteria (RDoC) into Depression Research. , 2015, Current opinion in psychology.

[27]  Prediction of treatment outcomes in major depressive disorder. , 2015, Expert review of clinical pharmacology.

[28]  E. Eriksson,et al.  Consistent superiority of selective serotonin reuptake inhibitors over placebo in reducing depressed mood in patients with major depression , 2015, Molecular Psychiatry.

[29]  Carolyn R Rohrer Vitek,et al.  Pharmacokinetic Pharmacogenetic Prescribing Guidelines for Antidepressants: A Template for Psychiatric Precision Medicine. , 2016, Mayo Clinic proceedings.

[30]  Helen S Mayberg,et al.  Effects of Patient Preferences on Outcomes in the Predictors of Remission in Depression to Individual and Combined Treatments (PReDICT) Study. , 2017, The American journal of psychiatry.

[31]  Helen S Mayberg,et al.  Functional Connectivity of the Subcallosal Cingulate Cortex And Differential Outcomes to Treatment With Cognitive-Behavioral Therapy or Antidepressant Medication for Major Depressive Disorder. , 2017, The American journal of psychiatry.

[32]  H. Walter,et al.  Research Domain Criteria (RDoC) , 2017, Der Nervenarzt.

[33]  Ulrike Kübler.  Structured Clinical Interview for DSM-IV (SCID) , 2020, Encyclopedia of Behavioral Medicine.